The New Horizon in Melanoma

Andrew D. Smith
Published: Wednesday, Dec 11, 2019
Jeffrey Weber, MD, PhD

Jeffrey Weber, MD, PhD
Early in this decade, Jeffrey S. Weber, MD, PhD, saw how well nivolumab (Opdivo) performed against advanced melanoma and recognized a good thing. He had a hunch the PD-1 inhibitor would reduce relapse rates by stimulating immune response against any cancer cells that escaped the surgeon’s knife.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication